Skip to main content

Drug Interactions between avanafil and Yohimbe

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

yohimbine avanafil

Applies to: Yohimbe (yohimbine) and avanafil

MONITOR: Concomitant use of multiple vasodilator drugs for the treatment of erectile dysfunction (ED) may increase the risk of additive adverse effects, including hypotension, dizziness, syncope, prolonged erection, or priapism. However, available data are conflicting. For example, approximately 4.9% and 7.1% of people in selected studies using single ingredient intracavernosal injections (ICIs) of papaverine reported experiencing painful/prolonged erections and priapism, respectively. Conversely, selected studies of people using ICIs containing papaverine and phentolamine reported an increase in the average rate of prolonged/painful erections to approximately 8.9%, but a reduction in the average rate of priapism to approximately 5.5%. Additionally, 1 case series reported an increase in dizziness and syncope when patients used both oral agents and ICIs to treat ED. Clinical data are not available for all possible combinations. The route of administration and amount of medication absorbed systemically may affect the clinical significance and severity of this interaction.

MANAGEMENT: Most clinical guidelines advise caution and closer clinical monitoring for patients on erectile dysfunction (ED) regimens that include multiple vasodilative agents due to the potential for additive adverse effects. Some drug manufacturers recommend avoiding combinations due to the potential risks and a lack of established data on safety. However, some of these medications are available as combinations (either commercially or via compounding) and some ED guidelines indicate that combination therapy may be appropriate in certain situations. Healthcare providers should refer to the product labeling and appropriate treatment guidelines for the most up to date information and recommendations; as well as, counsel patients on potential adverse effects and what to do should they occur.

References (14)
  1. (2021) "Product Information. Papaverine Hydrochloride (papaverine)." Oryza Pharmaceuticals Inc
  2. (2023) "Product Information. Invicorp (aviptadil-fentolamin)." Evolan Pharma AB
  3. (2023) "Product Information. Caverject (alprostadil)." Pfizer U.S. Pharmaceuticals Group
  4. (2021) "Product Information. Caverject (alprostadil)." Pfizer Ltd
  5. (2019) "Product Information. Caverject Impulse (alprostadil)." Pfizer Australia Pty Ltd, pfpcaviv10519
  6. (2018) "Product Information. Muse (alprostadil)." Meda Pharmaceuticals
  7. (2018) "Product Information. Muse (alprostadil)." Viatris UK Healthcare Ltd
  8. Dhir RR, Lin HC, Canfield SE, Wang R (2011) "Combination therapy for erectile dysfunction: an update review." Asian J Androl, 13, p. 382-90
  9. Al-Adl AM, Abdel-Wahab O, El-Karamany T, Aal AA (2011) "Combined intracavernous vasoactive drugs and sildenafil citrate in treatment of severe erectile dysfunction not responding to on-demand monotherapy." Arab J Urol, 9, p. 153-8
  10. Karakus S, Burnett AL (2024) The medical and surgical treatment of erectile dysfunction: a review and update. https://www.canjurol.com/abstract.php?ArticleID=&version=1.0&PMID=32876000
  11. Burnett AL, Nehra A, Breau RH, et al. (2018) "Erectile Dysfunction: AUA Guideline." J Urol, 200, p. 633-41
  12. Hackett G, Kirby M, Wylie K, et al. (2018) "British society for sexual medicine guidelines on the management of erectile dysfunction in men - 2017." J Sex Med, 15, p. 430-57
  13. Lowy M, Ramanathan V (2024) Erectile dysfunction: causes, assessment and management options. https://australianprescriber.tg.org.au/articles/erectile-dysfunction-causes-assessment-and-management-options.html
  14. Domes T, Najafabadi BT, Roberts M, et al. (2021) "Canadian urological association guideline: erectile dysfunction." Can Urol Assoc J, 10, p. 310-22

Drug and food interactions

Moderate

avanafil food

Applies to: avanafil

GENERALLY AVOID: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other. Administration of avanafil 200 mg with alcohol at a dose of 0.5 g/kg (equivalent to approximately 3 ounces of 80-proof vodka in a 70-kg male; consumed within 15 minutes in study subjects, providing blood alcohol levels of 0.057%) resulted in additional maximum supine systolic/diastolic blood pressure decreases of 3.5/4.5 mm Hg and additional maximum pulse rate increase of 9.3 bpm compared to alcohol alone, but did not cause orthostatic hypotension or dizziness. The plasma concentrations of alcohol were not affected. Sildenafil 50 mg and vardenafil 20 mg reportedly did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08% and in healthy volunteers administered alcohol at a dose of 0.5 g/kg, respectively. Alcohol and vardenafil plasma levels were not altered when dosed simultaneously.

GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of avanafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

MANAGEMENT: Patients taking avanafil should avoid consuming large amounts of alcohol, which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice. Some authorities advise that grapefruit juice should be avoided within 24 hours prior to taking avanafil.

References (5)
  1. (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
  2. (2003) "Product Information. Levitra (vardenafil)." Bayer
  3. (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  5. (2012) "Product Information. Stendra (avanafil)." Vivus LLC.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Erectile dysfunction agents

Therapeutic duplication

The recommended maximum number of medicines in the 'erectile dysfunction agents' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'erectile dysfunction agents' category:

  • avanafil
  • Yohimbe (yohimbine)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.